<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc J Afr</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc J Afr</journal-id><journal-id journal-id-type="publisher-id">TBC</journal-id><journal-title-group><journal-title>Cardiovascular Journal of Africa</journal-title></journal-title-group><issn pub-type="ppub">1995-1892</issn><issn pub-type="epub">1680-0745</issn><publisher><publisher-name>Clinics Cardive Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3767938</article-id><article-id pub-id-type="doi">10.5830/CVJA-2013-043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Topics</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Gender and ethnic differences in the control of hyperlipidaemia and other vascular risk factors: insights from the CEntralised Pan-South African survey on tHE Under-treatment of hypercholeSterolaemia (CEPHEUS SA) study </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rapeport</surname><given-names>Naomi</given-names></name><degrees>MB BCh, FCP, FACP</degrees><email>nrapeport@global.co.za</email><aff>Milpark Hospital, Johannesburg, South Africa</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Schamroth</surname><given-names>Colin Leslie</given-names></name><degrees>MB BCh, FCP, MMed</degrees><aff>Milpark Hospital, Johannesburg, South Africa</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Dirk</surname><given-names>Jacobus Blom</given-names></name><degrees>MB ChB, MMed, FCP (SA), PhD</degrees><aff>Division of Lipidology, Department of Medicine, University of Cape Town, South Africa</aff></contrib></contrib-group><pub-date pub-type="ppub"><month>8</month><year>2013</year></pub-date><volume>24</volume><issue>6</issue><fpage>238</fpage><lpage>242</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cvja.co.za">www.cvja.co.za</ext-link><history><date date-type="received"><day>28</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2010 Clinics Cardive Publishing</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract abstract-type="executive-summary"><sec id="st1"><title><text><SENT sid="1" pm="."><plain>Aim </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>The aim of the CEntralised Pan-South African survey on tHE Under-treatment of hypercholeSterolaemia (CEPHEUS SA) was to evaluate the current use and efficacy of lipid-lowering drugs (LLDs) in urban patients of different ethnicity with hyperlipidaemia, and to identify possible patient characteristics associated with failure to achieve low-density lipoprotein cholesterol (LDL-C) targets. </plain></SENT>
<SENT sid="3" pm="."><plain>There is little published data on LDL-C attainment from developing countries. </plain></SENT>
</text></SecTag></p></sec><sec id="st2"><title><text><SENT sid="4" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>The survey was conducted in 69 study centres in South Africa and recruited consecutive patients who had been prescribed LLDs for at least three months with no dose adjustment for six weeks. </plain></SENT>
<SENT sid="6" pm="."><plain>All patients provided written consent. </plain></SENT>
<SENT sid="7" pm="."><plain>One visit was scheduled for data collection, including fasting lipid and glucose, and HbA1c levels. </plain></SENT>
</text></SecTag></p></sec><sec id="st3"><title><text><SENT sid="8" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>Of the 3 001 patients recruited, 2 996 were included in the final analyses; 1 385 subjects were of Caucasian origin (818 male), 510 of African ancestry (168 male), 481 of mixed ancestry (222 male) and 620 of Asian origin (364 male). </plain></SENT>
<SENT sid="10" pm="."><plain>Only 60.5% of patients on LLDs for at least three months achieved the LDL-C targets recommended by the NCEP ATP III/2004 updated NCEP ATP III guidelines and 52.3% the fourth JETF/South African guidelines. </plain></SENT>
<SENT sid="11" pm="."><plain>African females were on average younger than females of other ethnic origins, and had the lowest smoking rates but the highest prevalence of obesity, hypertension, the metabolic syndrome and diabetes mellitus (DM), with the worst glycaemic control. </plain></SENT>
<SENT sid="12" pm="."><plain>Although women were less likely than men to reach goal [OR 0.65 (CI 0.54–0.77), p &lt; 0.001 for NCEP ATP III guidelines and OR 0.76 (CI 0.64–0.91), p &lt; 0.003 for fourth JETF guidelines], women of African ancestry were just as likely not to reach goal as their Caucasian counterparts. </plain></SENT>
</text></SecTag></p></sec><sec id="st4"><title><text><SENT sid="13" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>The results of this survey highlight the sub-optimal lipid control achieved in many South African patients, and profile important gender and ethnic differences. </plain></SENT>
<SENT sid="15" pm="."><plain>Control of cardiovascular disease risk factors across gender and ethnic groups remains poor. </plain></SENT>
</text></SecTag></p></sec></abstract></article-meta></front><body><sec id="s1"><title><text><SENT sid="16" pm="."><plain>Abstract </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>Elevated serum lipid levels have been identified as one of the modifiable risk factors in the aetiology of cardiovascular disease (CVD). </plain></SENT>
<SENT sid="18" pm="."><plain>The INTERHEART study established that elevated lipid levels was the greatest contributor to the development of myocardial infarction worldwide.1 Multiple studies have evaluated the control of serum lipid levels in clinical practice but these studies originate almost exclusively from the developed nations of North America and Europe.2-8 Cardiovascular risk-factor control is poorly studied in developing nations, and in particular, knowledge of the control of lipid levels is largely unknown. </plain></SENT>
<SENT sid="19" pm="."><plain>In the limited published data, there is no specific information on gender and/or ethnic differences.9 </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Different authorities, such as the Joint European Task Force (JETF) and the United States National Cholesterol Educational Program Adult Treatment Panel III (NCEP ATP III) have developed clinical guidelines for the management of CVD risk, and there are extensive data showing that modification of risk factors can delay the development of CVD or prevent recurrent events in those with CVD at baseline.10-13 Over time, these guidelines have proposed progressively lower targets for CVD risk factors on the basis of evidence from clinical studies demonstrating that cardiovascular risk is further reduced by more rigorous risk-factor control. </plain></SENT>
<SENT sid="21" pm="."><plain>Aggressive low-density lipoprotein cholesterol (LDL-C) lowering remains the cornerstone of lipid management. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>The CEntralised Pan-South African survey on tHE Undertreatment of hypercholeSterolaemia (CEPHEUS SA) was initiated to detect and quantify the degree of undertreatment of hypercholesterolaemia in South Africa, and the full overall results have been published.14 This study afforded us an opportunity to study both gender and ethnic differences in the prevalence of these CVD risk factors in a developing world population on drug treatment for elevated serum lipid levels, and forms the basis of this article. </plain></SENT>
</text></p></sec><SecTag type="METHODS"><sec sec-type="methods" id="s2a"><title><text><SENT sid="23" pm="."><plain>Methods </plain></SENT>
</text></title><p><text><SENT sid="24" pm="."><plain>CEPHEUS was a non-interventional study conducted in South Africa between November 2009 and April 2010. </plain></SENT>
<SENT sid="25" pm="."><plain>To be representative of the varied population demographics in the country, 101 investigators in 69 urban study centres were involved in recruiting patients; 67 were general/primary healthcare practitioners, 13 were cardiologists, seven endocrinologists, and 14 internists/specialist physicians. </plain></SENT>
<SENT sid="26" pm="."><plain>Investigators were drawn from both the public and private sectors. </plain></SENT>
<SENT sid="27" pm="."><plain>Public sector sites were located in tertiary level referral hospitals. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Subjects 18 years or older who had been receiving lipidlowering drugs (LLDs) for at least three months (without dose adjustments for at least six weeks) were eligible. </plain></SENT>
<SENT sid="29" pm="."><plain>Consecutive patients who came for their regular scheduled visit to the doctor/clinic were invited to participate in the survey. </plain></SENT>
<SENT sid="30" pm="."><plain>Patients who agreed to participate provided informed written consent. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>CEPHEUS was a single-visit non-interventional study. </plain></SENT>
<SENT sid="32" pm="."><plain>Each patient’s record form documented patient demographics, current LLD treatment, smoking status, known diabetes mellitus (DM), family history of premature vascular disease, known arterial hypertension (HT) and cardiovascular medical history. </plain></SENT>
<SENT sid="33" pm="."><plain>Physical examination by the investigator was limited to measurement of height, weight, waist circumference and blood pressure. </plain></SENT>
<SENT sid="34" pm="."><plain>A fasting blood sample was drawn to evaluate the serum lipid profile [total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides and apolipoprotein (apo) AI and apo B], fasting blood glucose (FG) and glycosylated haemoglobin (HbA1c) levels. </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>The primary endpoint was the percentage of patients who achieved the LDL-C goals according to either the NCEP ATP III/2004 updated NCEP ATP III guidelines or the fourth JETF/South African guidelines, which were current in South Africa at the time the CEPHEUS SA study was conducted. </plain></SENT>
<SENT sid="36" pm="."><plain>Secondary endpoints included achievement of LDL-C goals in patients with and without features of the metabolic syndrome, and primary versus secondary prevention. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>The parent study (CEPHEUS-Europe) has been registered with the US National Institutes of Health (ClinicalTrials.gov), number NCT00542867. </plain></SENT>
<SENT sid="38" pm="."><plain>The CEPHEUS study was sponsored by AstraZeneca. </plain></SENT>
<SENT sid="39" pm="."><plain>The sponsor oversaw data collection and monitored study sites. </plain></SENT>
<SENT sid="40" pm="."><plain>The authors had full access to the study database and all analyses reported here were performed independently of the sponsor. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="s2b"><title><text><SENT sid="41" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>We subdivided the cohort by gender and ethnicity for the purposes of this analysis. </plain></SENT>
<SENT sid="43" pm="."><plain>The four major ethnic groups in South Africa were black Africans, Caucasians, Asians (including patients of Indian descent) and patients with mixed ancestry. </plain></SENT>
<SENT sid="44" pm="."><plain>The risk category was determined for each patient and we calculated a dichotomous variable for each patient indicating whether their LDL-C had reached the guideline mandated target level. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>We generated descriptive statistics for all clinical and laboratory parameters, following subdivision by gender only, and then following subdivision by both ethnicity and gender. </plain></SENT>
<SENT sid="46" pm="."><plain>We analysed the effect of ethnicity and gender on goal attainment using logistic regression with the logit function in a model that incorporated ethnicity and gender simultaneously. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>We calculated odds ratios and 95% confidence intervals for the probability of not attaining LDL-C goal. </plain></SENT>
<SENT sid="48" pm="."><plain>The probability of not attaining LDL-C goal was referenced against Caucasian ethnicity and male gender, for which the odds ratio was set as 1. </plain></SENT>
<SENT sid="49" pm="."><plain>All p-values are two-sided and we regarded p &lt; 0.05 as statistically significant. </plain></SENT>
<SENT sid="50" pm="."><plain>All analyses were performed with Statistica [StatSoft Inc (2011), STATISTICA (data analysis software system) version 10, www.statsoft.com]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s3"><title><text><SENT sid="51" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>A total of 3 001 patients consented to participate in the survey. </plain></SENT>
<SENT sid="53" pm="."><plain>Full data sets were available from 2 996 patients and form the basis of this report. </plain></SENT>
<SENT sid="54" pm="."><plain>About two-thirds of patients were recruited from the private healthcare sector, with the remaining one-third coming from public sector institutions. </plain></SENT>
</text></p><p><text><SENT sid="55" pm="."><plain>Demographic, anthropometric and clinical data are shown in Table 1. </plain></SENT>
<SENT sid="56" pm="."><plain>Of the total group, 47.1% had known DM but 2.4% of patients who did not give a history of DM had FG levels that would qualify for the diagnosis of DM. </plain></SENT>
<SENT sid="57" pm="."><plain>Glycaemic control in patients who gave a history of DM was generally poor, with a mean HbA1c level of 8.33%. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1</label><caption><title><text><SENT sid="58" pm="."><plain>Baseline Characteristics </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="59" pm="."><plain>Characteristics </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="60" pm="."><plain>Entire study </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="61" pm="."><plain>Caucasian </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="62" pm="."><plain>African </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="63" pm="."><plain>Mixed ancestry </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="64" pm="."><plain>Asian </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>Female </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>Number </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>1572 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>1424 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>818 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>567 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>168 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>342 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>222 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>259 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>364 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>256 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>Mean age (years) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>59.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>59.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>60.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>62.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>57.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>57.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>58.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>59.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>56.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>58.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>Current smoker (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>18.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>10.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>15.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>14.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>15.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>2.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>25.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>19.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>21.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>5.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>Family history of vascular disease (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>27.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>29.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>29.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>36.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>4.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>11.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>25.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>30.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>39.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>37.5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Mean body mass index (kg/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>29.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>30.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>30.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>29.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>29.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>34.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>29.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>31.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>27.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>29.4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Mean waist circumference (cm) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>101.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>101.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>105.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>95.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>101.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>102.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>101.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>100.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>99.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>97.6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>Known diabetes mellitus (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>45.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>48.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>34.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>26.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>70.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>74.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>54.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>54.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>38.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>55.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>Known systemic hypertension (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>68.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>74.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>64.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>64.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>84.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>88.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>76.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>84.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>65.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>67.9 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>History of coronary heart disease (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>45.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>23.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>46.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>19.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>19.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>14.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>58.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>38.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>49.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>31.6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>History of cerebrovascular disease (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>5.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>4.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>5.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>4.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>5.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>6.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>6.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>4.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>6.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>4.2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>History of peripheral arterial disease (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>6.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>3.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>7.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>3.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>3.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>2.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>6.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>6.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>3.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>2.7 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="196" pm="."><plain>The prevalence of a history of HT in this study was 71.6%. </plain></SENT>
<SENT sid="197" pm="."><plain>The mean systolic blood pressure in the entire study cohort was 133.2 mmHg, with a diastolic pressure of 80.2 mmHg. </plain></SENT>
<SENT sid="198" pm="."><plain>In those subjects with a history of HT (Table 2), the mean systolic blood pressure was 136.1 mmHg, with a diastolic pressure of 81.3 mmHg. </plain></SENT>
<SENT sid="199" pm="."><plain>African-ancestry males had the highest systolic blood pressure and females of mixed ancestry the highest diastolic blood pressure but the inter-ethnic differences were small. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="anchor"><label>Table 2</label><caption><title><text><SENT sid="200" pm="."><plain>Control Of Diabetes And Hypertension </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="201" pm="."><plain>Condition </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="202" pm="."><plain>Entire study </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="203" pm="."><plain>Caucasian </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="204" pm="."><plain>African </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="205" pm="."><plain>Mixed ancestry </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="206" pm="."><plain>Asian </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>Female </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" colspan="11" rowspan="1"><text><SENT sid="217" pm="."><plain>Diabetic patients </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>Number </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>718 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>690 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>279 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>152 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>118 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>256 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>120 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>139 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>200 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>141 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>Glucose (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>7.93 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>8.44 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>7.46 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>8.08 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>8.12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>9.12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>8.17 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>7.86 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>8.24 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>8.19 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>HbA1c (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>7.94 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>8.73 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>7.33 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>7.64 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>8.66 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>9.60 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>8.19 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>8.52 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>8.26 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>8.57 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="11" rowspan="1"><text><SENT sid="251" pm="."><plain>Hypertensive patients </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Number </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>1081 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>1063 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>529 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>367 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>142 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>304 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>170 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>218 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>240 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>174 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>Systolic blood pressure (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>134.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>137.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>135.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>135.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>137.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>137.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>136.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>141.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>130.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>135.3 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>Diastolic blood pressure (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>81.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>80.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>82.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>79.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>83.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>81.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>81.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>81.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>79.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>80.0 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="285" pm="."><plain>More Caucasian patients were receiving LLDs for primary prevention compared to those of African ancestry, few of whom were on treatment for primary prevention. </plain></SENT>
<SENT sid="286" pm="."><plain>The majority were receiving treatment for the CVD risk equivalent of DM. </plain></SENT>
</text></p><p><text><SENT sid="287" pm="."><plain>The percentage of African patients who were on LLDs for coronary artery disease (CAD) was lower than that seen in the other ethnic groups. </plain></SENT>
<SENT sid="288" pm="."><plain>The prevalence of CAD was higher in males than in females in all ethnic groups. </plain></SENT>
<SENT sid="289" pm="."><plain>Among male participants, CAD rates were highest in men of Caucasian, Asian and mixed ancestry. </plain></SENT>
<SENT sid="290" pm="."><plain>Among the women, the highest prevalence of CAD was in women of mixed and Asian ancestry. </plain></SENT>
<SENT sid="291" pm="."><plain>Few African patients gave a family history of CAD and the percentage of smokers was also lowest among the African patients. </plain></SENT>
<SENT sid="292" pm="."><plain>Most patients (95.9%) were on LLD monotherapy, with this being almost exclusively (98.9%) statin based. </plain></SENT>
</text></p><p><text><SENT sid="293" pm="."><plain>The on-treatment lipid and FG values are listed in Table 3. </plain></SENT>
<SENT sid="294" pm="."><plain>Overall, patients of African ancestry had lower TC, LDL-C, and non-HDL-C levels and higher FG levels than subjects of other ethnic groups. </plain></SENT>
<SENT sid="295" pm="."><plain>In the cohort with DM (Table 2), the Africanancestry patients had the highest levels of HbA1c, both for males and females. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="anchor"><label>Table 3</label><caption><title><text><SENT sid="296" pm="."><plain>Laboratory Results </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="297" pm="."><plain>Laboratory parameters </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="298" pm="."><plain>Entire study </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="299" pm="."><plain>Caucasian </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="300" pm="."><plain>African </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="301" pm="."><plain>Mixed ancestry </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="302" pm="."><plain>Asian </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>Female </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>Total cholesterol (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>4.72 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>5.06 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>4.75 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>5.26 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>4.44 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>4.57 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>4.78 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>5.20 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>4.75 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>5.13 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>LDL cholesterol (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>2.63 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>2.85 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>2.62 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>2.93 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>2.44 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>2.55 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>2.65 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>3.01 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>2.72 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>2.91 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>HDL cholesterol (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>1.21 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>1.41 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>1.25 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>1.53 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>1.19 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>1.31 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>1.15 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>1.36 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>1.19 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>1.33 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>Triglycerides (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>2.01 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>1.79 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>2.03 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>1.80 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>1.83 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>1.55 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>2.31 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>1.83 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>1.88 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>1.99 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>Non-HDL cholesterol (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>3.65 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>3.73 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>3.25 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>3.26 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>3.63 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>3.84 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>3.56 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>3.80 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>Glucose (mmol/l) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>6.52 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>6.76 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>6.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>5.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>7.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>8.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>6.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>6.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>7.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>7.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>Glycosylated haemoglobin (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>7.34 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>638 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>6.31 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>8.74 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>7.48 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>7.91 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="386" pm="."><plain>The primary outcome or percentage of patients reaching LDL-C targets is given in Table 4. </plain></SENT>
<SENT sid="387" pm="."><plain>Overall 60.5% of patients reached goal as per the NCEP ATP II guidelines and 52.3% according to the JETF guidelines. </plain></SENT>
<SENT sid="388" pm="."><plain>Differences in attainment of goal were noted. </plain></SENT>
<SENT sid="389" pm="."><plain>Patients of mixed ancestry were less likely to get to either of the two goals, with the exception of mixed-ancestry males, who had similar not-at-goal percentages as the male patients of Asian ancestry. </plain></SENT>
<SENT sid="390" pm="."><plain>Females subjects were less likely to get to goal, both for the NCEP ATP III [OR 0.65 (CI 0.54–0.77), p &lt; 0.001] and JETF [OR 0.76 (CI 0.64–0.91), p &lt; 0.003] guidelines. </plain></SENT>
<SENT sid="391" pm="."><plain>This difference was maintained across the various ethnic groups. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T4" orientation="portrait" position="anchor"><label>Table 4</label><caption><title><text><SENT sid="392" pm="."><plain>Attainment Of Primary Goal (%) </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="393" pm="."><plain>Guidelines </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="394" pm="."><plain>Entire study </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="395" pm="."><plain>Caucasian </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="396" pm="."><plain>African </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="397" pm="."><plain>Mixed ancestry </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="398" pm="."><plain>Asian </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>Female </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>NCEP ATP III </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>63.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>56.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>67.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>61.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>68.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>60.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>61.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>41.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>58.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>52.7 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>EAS/ESC </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>55.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>49.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>57.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>50.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>62.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>55.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>44.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>42.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>51.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>48.0 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="431" pm="."><plain>The secondary outcomes or percentages of patients receiving LLDs with the metabolic syndrome, and the breakdown of those receiving LLDs for primary versus secondary prevention is given in Table 5. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T5" orientation="portrait" position="anchor"><label>Table 5</label><caption><title><text><SENT sid="432" pm="."><plain>Secondary Outcome Variables </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="433" pm="."><plain>Variables </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="434" pm="."><plain>Entire study </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="435" pm="."><plain>Caucasian </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="436" pm="."><plain>African </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="437" pm="."><plain>Mixed ancestry </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"><text><SENT sid="438" pm="."><plain>Asian </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>Female </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>Metabolic syndrome (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>65.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>71.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>62.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>55.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>72.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>88.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>71.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>77.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>63.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>78.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>Primary prevention (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>40.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>48.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>47.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>66.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>32.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>24.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>32.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>44.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>34.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>45.7 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>Secondary prevention (including DM) (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>59.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>51.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>52.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>33.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>67.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>75.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>67.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>56.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>65.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>54.3 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s4a"><title><text><SENT sid="482" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="483" pm="."><plain>The World Health Organisation has indicated that cardiovascular disease will be the number one cause of mortality in the developing world by 2020.15 Subjects with cardiovascular disease in underdeveloped countries tend to exhibit mortality 10 or more years before their counterparts from the developed nations.16 These factors indicate that it is imperative to address all cardiovascular risk factors aggressively if there is to be any curtailment of the looming epidemic. </plain></SENT>
</text></p><p><text><SENT sid="484" pm="."><plain>This survey, representing patients in a developing country, indicates that a large proportion of patients on LLDs are not reaching the accepted LDL-C goals. </plain></SENT>
<SENT sid="485" pm="."><plain>While these percentages are not dissimilar to those from other studies in Europe, they are below what is currently achieved in North America. </plain></SENT>
<SENT sid="486" pm="."><plain>The percent of patients at goal in North America has risen over the course of six years, from the NHANES survey of 1999/2000 and the follow up conducted in 2005/2006, indicating that increased awareness and education can result in a greater percentage of patients reaching LDL-C goals, despite the targets becoming more stringent. </plain></SENT>
</text></p><p><text><SENT sid="487" pm="."><plain>The current study indicates both ethnic and gender variances in cardiovascular risk-factor distribution and control in South Africa. </plain></SENT>
<SENT sid="488" pm="."><plain>Smoking was less prevalent in those of African ancestry and very few black females were smokers. </plain></SENT>
<SENT sid="489" pm="."><plain>In general black subjects used fewer cigarettes than their Caucasian counterparts (possibly due to economic constraints). </plain></SENT>
<SENT sid="490" pm="."><plain>The South African Heart of Soweto study confirms that African patients have the lowest smoking prevalence, with patients of mixed ancestry twice as likely, and Caucasian patients three-fold more likely to be current smokers.17 In the current study of patient on LLDs, patients of mixed ancestry had the highest prevalence of smoking among both males and females, followed by Asian males. </plain></SENT>
</text></p><p><text><SENT sid="491" pm="."><plain>The majority of black subjects did not have a family history of premature heart disease, which probably reflects the evolution of the epidemiological transition in an urbanising population, compared to Caucasians, Asians and patients of mixed ethnicity. </plain></SENT>
<SENT sid="492" pm="."><plain>The Heart of Soweto study also noted that African patients were least likely to be diagnosed with CAD, and showed similar data to CEPHEUS SA for the Asian patients, who had the highest prevalence of a family history of vascular disease. </plain></SENT>
</text></p><p><text><SENT sid="493" pm="."><plain>Control of DM was particularly poor in both male and female African subjects compared with their ethnic counterparts. </plain></SENT>
<SENT sid="494" pm="."><plain>This may have been due to differences in access to guideline-based management protocols. </plain></SENT>
<SENT sid="495" pm="."><plain>Despite a high prevalence of the metabolic syndrome in African females, with poor control of DM, their TG levels were the lowest of all subjects – male and female. </plain></SENT>
</text></p><p><text><SENT sid="496" pm="."><plain>The Heart of Soweto study noted that patients of African descent had significantly lower total cholesterol (TC), LDL-C and triglyceride (TG) levels compared to other ethnicities.17 These patients were not receiving LLDs. </plain></SENT>
<SENT sid="497" pm="."><plain>In CEPHEUS SA, in the African-ancestry group, the TGs were not elevated despite a high prevalence of DM with poor control. </plain></SENT>
<SENT sid="498" pm="."><plain>This would lend credence to the finding that this population group may inherently have low TG levels, and the influence of DM on TGs may be muted. </plain></SENT>
</text></p><p><text><SENT sid="499" pm="."><plain>The Heart of Soweto study confirmed a high prevalence of obesity in patients of African ancestry (43% of the patients having a body mass index greater than 30 kg/m2). </plain></SENT>
<SENT sid="500" pm="."><plain>This substantial burden of obesity among African subjects points to an elevated risk for the future development of DM. </plain></SENT>
<SENT sid="501" pm="."><plain>Given that DM in this group is poorly controlled, the ameliorating influence of lipid-lowering therapy on future cardiovascular risk could potentially be undermined, or at the very least minimised. </plain></SENT>
</text></p><p><text><SENT sid="502" pm="."><plain>The number of African-ancestry patients who had CAD was low in proportion to the other ethnic groups; however these percentages reflect a change in the prevalence of a disease that was previously considered to be rare in this population. </plain></SENT>
<SENT sid="503" pm="."><plain>Other studies from South Africa have indicated a prevalence of CAD of less than 10% in the African population.18 The prevalence of CAD in African subjects receiving LLDs in the current study was 15.9%. </plain></SENT>
</text></p><p><text><SENT sid="504" pm="."><plain>The INTERHEART Africa study noted that patients of African ancestry presented with myocardial infarction a mean of 3.8 years earlier than patients from the overall INTERHEART study, and also found no inter-ethnic or gender differences.1,19 Although data for the INTERHEART Africa study were drawn from patients from sub-Saharan countries, more than 80% of subjects were from South Africa, indicating that the data may be comparable to the current CEPHEUS SA study. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec id="s4b"><title><text><SENT sid="505" pm="."><plain>Limitations </plain></SENT>
</text></title><p><text><SENT sid="506" pm="."><plain>This study had the same limitations that apply to many surveys that differ fundamentally from formal prospective studies. </plain></SENT>
<SENT sid="507" pm="."><plain>The study population was drawn from those already on LLDs and cannot be extrapolated to the general population. </plain></SENT>
<SENT sid="508" pm="."><plain>Although attempts were made to sample patients from as wide a spectrum as possible, potential selection bias may still have occurred. </plain></SENT>
<SENT sid="509" pm="."><plain>All centres were located in urban areas, and the applicability to patients of rural origin cannot be assumed. </plain></SENT>
</text></p><p><text><SENT sid="510" pm="."><plain>The public sector provides healthcare to about 80% of the South African population but it made up only about one-third of the sample. </plain></SENT>
<SENT sid="511" pm="."><plain>Similarly, the study population does not strictly reflect the ratios of the different ethnic groups residing in South Africa. </plain></SENT>
<SENT sid="512" pm="."><plain>However all previous studies on lipid-lowering therapy in South Africa were predominantly Caucasian based. </plain></SENT>
<SENT sid="513" pm="."><plain>Private-sector patients were recruited from a wide variety of both specialist and non-specialist practices. </plain></SENT>
<SENT sid="514" pm="."><plain>The public-sector patients were predominantly recruited from tertiary-care lipid and diabetes clinics. </plain></SENT>
<SENT sid="515" pm="."><plain>The majority of African patients came from the public sector. </plain></SENT>
</text></p><p><text><SENT sid="516" pm="."><plain>Several private-sector centres had practitioners who dealt predominantly with patients with DM, and this could have further swayed the emphasis of the results on the diabetic cohort. </plain></SENT>
<SENT sid="517" pm="."><plain>DM is often associated with an increase in body mass index and other anthropometric measures of obesity, and data from a cohort with a high prevalence of DM may therefore not be reflective of the general population. </plain></SENT>
</text></p><p><text><SENT sid="518" pm="."><plain>As the veracity of the patient questionnaires was not tested, the validity of the CVD history may have been inaccurate. </plain></SENT>
<SENT sid="519" pm="."><plain>Measured clinical parameters (such as blood pressure) were from a single visit and methods of measurement were not standardised or checked, and therefore inaccuracies could have arisen. </plain></SENT>
<SENT sid="520" pm="."><plain>Causal correlations were not established, and relationships should therefore be interpreted with caution. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusion" id="s5"><title><text><SENT sid="521" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="522" pm="."><plain>Management of lipid-lowering treatment in South Africa is sub-optimal, and in general lags behind control achieved in the more developed nations. </plain></SENT>
<SENT sid="523" pm="."><plain>Furthermore, other cardiovascular risk factors are not receiving due attention and their prevalence in this population remains high. </plain></SENT>
<SENT sid="524" pm="."><plain>For any serious impact to be made on the looming epidemic of cardiovascular disease in the underdeveloped world, more attention needs to be focused on more aggressive treatment of dyslipidaemia as well as the other cardiovascular risk factors and, in particular, diabetes mellitus and obesity. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="525" pm="."><plain>The authors acknowledge the participation of all the investigators who participated in the study. </plain></SENT>
<SENT sid="526" pm="."><plain>Ms Michelle Nortje of AstraZeneca Pharmaceuticals was most helpful in the acquisition of data. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="R01"><text><SENT sid="527" pm="."><plain>1YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study.Lancet200436493795215364185 </plain></SENT>
</text></ref><ref id="R02"><text><SENT sid="528" pm="."><plain>2KuklinaEYoonPKeenanNTrends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006.J Am Med Assoc20093021921042110 </plain></SENT>
</text></ref><ref id="R03"><text><SENT sid="529" pm="."><plain>3KotsevaKWoodDDe BackerGEUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.J Cardiovasc Risk200916121137 </plain></SENT>
</text></ref><ref id="R04"><text><SENT sid="530" pm="."><plain>4GittADrexelHFeelyJHigh prevalence of persistent lipid abnormalities in high-risk patients treated with statins in Europe and Canada: results of the Dyslipidemia International Study (abstract).J Am Coll Cardiol2009A372 </plain></SENT>
</text></ref><ref id="R05"><text><SENT sid="531" pm="."><plain>5PearsonTLauroraIChuHet al.The Lipid Treatment Assessment Project (L-TAP): a multi-centre survey to evalulate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Arch Int Med200016045946710695686 </plain></SENT>
</text></ref><ref id="R06"><text><SENT sid="532" pm="."><plain>6Van GanseELaforestLAlemaoEet al.Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.Curr Med Res Opin20052191389139916197657 </plain></SENT>
</text></ref><ref id="R07"><text><SENT sid="533" pm="."><plain>7HermansMCabenzasMStrandbergTet al.Centralized Pan-European survey on the under-treatment of hypercholesterolemia (CEPHEUS): overall findings from eight countries.Curr Med Res Opin201026244545420001658 </plain></SENT>
</text></ref><ref id="R08"><text><SENT sid="534" pm="."><plain>8BandegasJLopez-GarciaEDallongevilleJet al.Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.Eur Heart J2011322143215221471134 </plain></SENT>
</text></ref><ref id="R09"><text><SENT sid="535" pm="."><plain>9RamjeethAButkowNRaalFet al.The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not-at-Goal study (SA-NAG).Cardiovasc J Afr2008192889418516354 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="536" pm="."><plain>10De BackerGAmbrosioniEBorch-JohnsenKet al.European guidelines on cardiovascular disease prevention in clinical practice. </plain></SENT>
<SENT sid="537" pm="."><plain>Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice.Eur Heart J2003241601161012964575 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="538" pm="."><plain>11Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III); final report.Circulation20021063143342112485966 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="539" pm="."><plain>12GrahamIAtarDBorch-JohnsenKet al.European guidelines on cardiovascular disease prevention in clinical practice: executive summary. </plain></SENT>
<SENT sid="540" pm="."><plain>Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice.Eur Heart J2007282375241417726041 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="541" pm="."><plain>13GrundySCleemanJMerzCet al.National heart, Lung and Blood Institute: American College of Cardiology Foundation; American Heart Association. </plain></SENT>
<SENT sid="542" pm="."><plain>Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation200411022723915249516 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="543" pm="."><plain>14RaalFSchamrothCBlomDMarxJRajputMHausMet al.CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia.Cardiovasc J Afr201122523424021922121 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="544" pm="."><plain>15BeagleholeRYachDGlobalisation and the prevention and control of non-communicable disease: the neglected diseases of adults.Lancet2003362938790390813678979 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="545" pm="."><plain>16ReddyKSCardiovascular disease in non-Western countries.New Engl J Med2004350242438244015190135 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="546" pm="."><plain>17SliwaKLyonsJGCarringtonMJLecourSet al.Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease.Cardiovasc J Afr20122338939522914997 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="547" pm="."><plain>18SliwaKWilkinsonDHansonDet al.Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study.Lancet200837191592218342686 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="548" pm="."><plain>19SteynKSliwaKHawkenSet al.Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study.Circulation20051123554356116330696 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
